Publication Year

Ring C, Blanchette A, Klaren WD, Fitch S, Haws L, Wheeler MW, DeVito MJ, Walker N, Wikoff D. 2023. A multi-tiered hierarchical Bayesian approach to derive toxic equivalency factors for dioxin-like compounds. Regul Toxicol Pharmacol 143(11):105464; doi: 10.1016/j.yrtph.2023.105464. PMID: 37516304.

Racz L, Mittal L, Perry CS, Blanchette A, Proctor D. Assessing sustainable applications of electric arc furnace steel slag as construction aggregate: Applications of probabilistic risk assessment and physiologically-based pharmacokinetic modeling. Poster presented at Society of Environmental Toxicology and Chemistry North America 44^th Annual Meeting, Louisville, KY, November 2023.

Thompson CM, Brorby G, Keig-Shevlin Z, Smith R, Franzen A, Ulrich K, Blanchette AD, Doepker C. 2023. Assessment of the in vivo genotoxic potential of three smoke flavoring primary product mixtures. Environ Mol Mutagen 64(8–9):420–431; doi: 10.1002/em.22576. PMID: 37916278.

Wikoff D, Ring C, DeVito M, Walker N, Birnbaum L, Haws L. 2023. Development and application of a systematic and quantitative weighting framework to evaluate the quality and relevance of relative potency estimates for dioxin-like compounds (DLCs) for human health risk assessment. Regul Toxicol Pharmacol 145:105500; doi: 10.1016/j.yrtph.2023.105500. PMID: 37866700.

Perry CS, Blanchette AD, Vivanco SN, Verwiel AH, Proctor DM. 2023. Use of physiologically based pharmacokinetic modeling to support development of an acute (24-hour) health-based inhalation guideline for manganese. Regul Toxicol Pharmacol 145:105518; doi: 10.1016/j.yrtph.2023.105518. PMID: 3786341.

Thompson CM, Kirman C, Harris MA. 2023. Derivation of oral cancer slope factors for hexavalent chromium informed by pharmacokinetic models and in vivo genotoxicity data. Regul Toxicol Pharmacol 145(Dec):105521; doi: 10.1016/j.yrtph.2023.105521. PMID: 37863416.

Heintz M, Thompson C, Fitch S, Rogers S, Wikoff D, Haws L, Rivera B. 2023. Protocol to develop updated oral toxicity values for HFPO-DA. OSF | Protocol_Oct2023.pdf.

Nelson CB, Jiang X, Suh M, Fryzek J. Prevention of respiratory syncytial virus hospitalizations (RSVH) in US infants who paid through Medicaid would have a greater benefit for Black, Hispanic, Asian/Pacific Islander, Native American and Other race/ethnicity infants, and have a substantial impact on overall RSVH burden and related costs: Rates of respiratory syncytial virus hospitalization (RSVH) among US infants by race/ethnicity and insurance payer, NIS 2018-2020. Poster 1536169, IDWeek 2023, Boston, MA, October 2023.

Blatt A, Suh M, Walter E, Jr., Wood CT, Espinosa C, Enriquez-Bruce ME,…, Movva N, Reichert H, Fryzek JP, et al. Seasonality of infant respiratory syncytial virus associated bronchiolitis around the US since the onset of COVID-19: Results from four US health systems 2016-17 through 2022-23. Poster 1535431, IDWeek 2023, Boston, MA, October 2023.

Henderson RG, Vincent M, Rivera BN, Bonn-Miller MO, Doepker C. 2023. Cannabidiol safety considerations: Development of a potential acceptable daily intake value and recommended upper intake limits for dietary supplement use. Regul Toxicol Pharmacol 144(Oct):105482; doi: 10.1016/j.yrtph.2023.105482. PMID: 37634699.